Cadisegliatin, a potential first-in-class oral treatment for type 1 diabetes, has been granted Breakthrough Designation by the FDA.
Klara Klein, MD, PhD
Advertisement
Klara Klein is an assistant professor of medicine and program director of Endo CRU at the University of North Carolina School of Medicine.
Articles by Klara Klein, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Interim Phase 3 VISIONARY Data Show Sibeprenlimab Preserved Kidney Function in IgA Nephropathy
2
POCUS is Standard of Care in Critical Care, With Rhea Votipka, NP
3
Trials and Guidelines Shaping Critical Care, With Rhea Votipka, NP
4
Navigating a New Era of PH Management as an APP, With Susanne McDevitt, DNP
5